Motus GI

Fort Lauderdale, Florida, United States All United States companies → — Founded 2008

Medical Device / Hardware Specialty-Focused AI

Colorectal Surgery Gastroenterology General Surgery

Publicly Held / Mature — $30.1M over 3 rounds (as of July 2026), $64.5 million across 5 funding rounds (as of Oct 2023), $3.50 mn (most recent funding round in March 2022)

Website Claim this company

Products

Pure-Vu

Motus GI

Gastroenterology AI

The Pure-Vu System is an FDA-approved device that facilitates intra-procedural cleansing of the GI tract to improve visualization during colonoscopies and gastroscopies, especially in cases of inadequate bowel preparation or GI bleeding.

Paid

See all 1 product →

About Motus GI

Motus GI Holdings, Inc. is a medical technology company that develops innovative solutions for gastrointestinal procedures, primarily focusing on enhancing colonoscopy outcomes. Their flagship product, the Pure-Vu System, is a U.S. FDA-cleared and CE-marked medical device designed to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and upper GI endoscopy procedures. The system integrates with standard and slim colonoscopes and gastroscopes, utilizing proprietary technologies such as pressure-controlled irrigation jets and efficient evacuation cycles to break up and remove debris, including blood and blood clots, thereby improving visualization for physicians.

For physicians, the Pure-Vu System aims to address critical challenges in endoscopy, particularly in cases of inadequate bowel preparation or emergent situations like GI bleeding. By enabling real-time intra-procedural cleansing, the system has the potential to reduce the incidence of delayed, aborted, or incomplete procedures, leading to more successful and higher-quality examinations. This can expedite diagnosis and treatment, improve patient outcomes, and enhance the cost-efficiency of procedures by minimizing the need for repeat endoscopies and reducing hospital bed turnover times. Motus GI also provides comprehensive support, including in-service programs and hands-on assistance, to ensure physicians and their staff are proficient in using the Pure-Vu System.

The company is actively engaged in clinical research and is targeting expansion in North America and Europe. Recent developments include the limited U.S. commercial launch of its Pure-Vu EVS Gastro and Gen 4 Colon system, which has reportedly doubled its active customer base. Motus GI continues to invest in new product developments and clinical trials to expand the indications of the Pure-Vu system, including for outpatient procedures.

Focus Areas

Improving endoscopy outcomes enhancing colonoscopy and upper GI endoscopy procedures facilitating gastrointestinal tract cleansing early detection and prevention of colorectal cancer and other diseases of the rectum and colon medical devices and equipment biotechnology monitoring equipment medical software.

Business Intelligence

Key Investors	Ascent Biomedical Ventures, Orchestra Medical Ventures, Jacobs Investments, Perceptive Advisors, Patrick Aisher, Darren R. Sherman, David Hochman
Partnerships	Sinai Hospital of Baltimore
Acquisitions	Motus Therapeutics (acquired by Allergan in 2016)
Technology	The Pure-Vu System is a medical device that integrates with standard and slim colonoscopes and gastroscopes. It utilizes irrigation and evacuation of debris through a disposable single-use over-sleeve and a workstation controller. The system features a novel irrigation technology with pulsed water and air jets, an efficient evacuation cycle, and auto-purge technology to prevent clogging.
FDA Clearances	4 (Pure-Vu System, Pure-Vu Slim Sleeve, Pure-Vu GEN2, Pure-Vu EVS Gastro and Gen 4 Colon) cleared products (estimated)

What Physicians Need to Know

Improving Endoscopy Outcomes

Motus GI's Pure-Vu System is designed to improve visualization during both colonoscopies and upper GI endoscopies by actively cleansing the GI tract during the procedure. This leads to a 38% to 96% improvement in visualization. The system aims to reduce the incidence of delayed, aborted, and incomplete procedures, and increase the quality of exams, especially in inadequately prepped patients.

Enhancing Colonoscopy Procedures

The Pure-Vu System is FDA-cleared for cleaning poorly prepped colons during colonoscopy procedures. It reduces the dependency on strict patient adherence to pre-colonoscopy protocols, which often involve an all-liquid diet and bowel-clearing substances. Clinical studies have shown that the Pure-Vu System significantly increases the number of patients with an adequate cleansing level, improving from a baseline of 38% to 96% in evaluated segments.

Facilitating Gastrointestinal Tract Cleansing

The Pure-Vu System utilizes a single-use sleeve that fits over most standard and slim endoscopes (colonoscopes and gastroscopes) and a reusable workstation. It produces pulses of water and air to break up blood, blood clots, and other debris, which are then removed through a suction channel. This intra-procedural cleansing allows physicians to more easily identify and treat sources of bleeding.

Early Detection and Prevention of Colorectal Cancer and Other Diseases

By improving visualization during colonoscopies, the Pure-Vu System aids in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. Inadequate bowel preparation can lead to increased adenoma miss rates and delayed diagnosis. The system's ability to achieve clear visualization helps mitigate these issues.

Medical Devices and Equipment

Motus GI's core product is the Pure-Vu System, a medical device that integrates with standard and slim colonoscopes and gastroscopes. The system includes a disposable EVS Flex Channel and an umbilical section connected to an external workstation. The workstation controls the delivery of irrigation fluids and gas, and the suction of fluids and debris.

Biotechnology

Motus GI is a medical technology company operating within the biotechnology and medical devices sector. Their innovation lies in the development of the Pure-Vu System, which leverages advanced technology for intra-procedural GI tract cleansing.

Medical Software

Motus GI has secured intellectual property covering system control software for its Pure-Vu System. They also offer a mobile app to provide on-demand support and educational resources to physicians and hospitals using the Pure-Vu System.

Physician Tip

For physicians, the Motus GI Pure-Vu System offers a significant advantage by providing on-demand, intra-procedural cleansing of the GI tract. This means less reliance on perfect patient bowel preparation, potentially reducing delayed or aborted procedures and improving the quality of the examination. The system's ability to clear blood, blood clots, and debris in real-time is particularly beneficial in emergent upper GI bleeding cases, allowing for quicker identification and treatment of bleed sources. The Pure-Vu EVS Flex Channel is designed to fit on most standard and slim endoscopes, preserving established procedural workflow. Furthermore, clinical studies have demonstrated significant improvements in visualization scores (Boston Bowel Preparation Scale) and a high success rate in completing colonoscopies. Motus GI also provides comprehensive training and educational resources, including on-demand proctorships and virtual sessions, to ensure efficient implementation and use of the system.

The Pure-Vu System is designed to integrate seamlessly with existing standard and slim colonoscopes and gastroscopes, minimizing disruption to established procedural workflows and techniques. The system consists of a disposable EVS Flex Channel that fits over the endoscope and connects to a reusable workstation. This design allows for easy adoption within current endoscopy suites without requiring significant changes to existing equipment. The company also offers a mobile app to provide on-demand support and resources, further enhancing the integration into clinical practice.

At a glance

Founded 2008

HQ Fort Lauderdale, Florida, United States · United States

Team size 20-23 (as of May 2026 / Dec 2022), 11-50 (as of Oct 2023)

CEO Timothy P. Moran

Funding Publicly Held / Mature — $30.1M over 3 rounds (as of July 2026), $64.5 million across 5 funding rounds (as of Oct 2023), $3.50 mn (most recent funding round in March 2022)

FDA clearances 4 (Pure-Vu System, Pure-Vu Slim Sleeve, Pure-Vu GEN2, Pure-Vu EVS Gastro and Gen 4 Colon) (estimated)

Products 1

Visit site

Products by Motus GI

1 product in the directory

Pure-Vu

Motus GI

Gastroenterology AI

Paid

Reviews & Opinions

No web reviews on file yet for Motus GI. Check back later for aggregated opinions from across the web.

Videos

News, demos, and interviews about Motus GI.

Loading videos...

Videos load interactively. If none appear, search YouTube for Motus GI →

View all on YouTube

Press & Coverage

Fierce Biotech

Motus GI gets FDA nod to expand colonoscopy cleansing system into upper GI endoscopies

Motus GI received FDA 510(k) clearance to expand the use of its Pure-Vu System to upper GI endoscopy procedures, in addition to its previously cleared use in colonoscopies. The system helps clear blood, blood clots, and debris to improve visibility during procedures.

2021-05

TMCnet (via GlobeNewswire)

Motus GI Announces Publication of Pure-Vuu00ae System Clinical Data in Peer-Reviewed Journal BMC Gastroenterology

Motus GI announced the publication of data from its REDUCE study in BMC Gastroenterology, highlighting the Pure-Vu System's 97% clinical success rate in improving bowel preparation quality in hospitalized patients undergoing colonoscopy.

2021-06

GlobeNewswire

Motus GI Receives FDA Clearance to Commercialize Pure-Vu EVS Gastro and Gen 4 Colon

Motus GI received FDA 510(k) clearance for technological advancements in its new Pure-Vu EVS Gastro and Gen 4 Colon system, featuring a larger suction channel, more efficient irrigation jets, and a smaller distal tip for enhanced flexibility.

2023-10

GlobeNewswire

Motus GI Announces 1-for-15 Reverse Stock Split

Motus GI Holdings, Inc. announced a 1-for-15 reverse stock split of its outstanding common stock, effective November 1, 2023.

2023-11

Nasdaq

Motus GI Holdings, Inc. Announces Pricing of $5.0 Million Public Offering

Motus GI Holdings, Inc. announced the pricing of a public offering of common stock and warrants, expecting to raise approximately $5.0 million in gross proceeds. The company intends to use the net proceeds for working capital and general corporate purposes.

2023-12

Motus GI Holdings, Inc. (via GlobeNewswire)

Motus GI Reports First Quarter 2024 Financial Results and Provides Corporate Update

Motus GI reported its Q1 2024 financial results, noting positive market acceptance for its Pure-Vuu00ae EVS Gastro and Gen 4 Colon systems, doubling active customers, and a growing sales pipeline. The company also announced a new patent issued by the USPTO.

2024-05

SEC.gov

Motus GI Holdings, Inc. Announces Plan of Liquidation and Dissolution

Motus GI Holdings, Inc. announced on June 6, 2024, that its board of directors approved a plan of liquidation and dissolution, subject to stockholder approval. The company will file a proxy statement with the SEC regarding this plan.

2024-06

Tracxn

Motus Gi - 2026 Funding Rounds & List of Investors

Motus GI has raised a total of $30.1 million over three funding rounds, including a Seed, an Early-Stage, and a Post IPO round. Their largest funding round was a Series A in February 2017.

2026-05

Frequently Asked Questions

What specific problems do Motus GI's products address in colonoscopy and upper GI endoscopy procedures?

Motus GI's primary product, the Pure-Vu System, is designed to improve the quality of colonoscopy preparations by providing on-demand, active cleansing of the colon during the procedure. This aims to enhance visualization, reduce the need for repeat procedures due to inadequate prep, and potentially improve adenoma detection rates. For upper GI endoscopy, the system can also assist in clearing blood or other debris to improve visualization in urgent situations.

How does the Pure-Vu System contribute to the early detection and prevention of colorectal cancer?

By significantly improving visualization during colonoscopies, the Pure-Vu System helps endoscopists identify polyps and other abnormalities that might otherwise be missed due to poor bowel preparation. This enhanced detection can lead to earlier intervention and removal of precancerous lesions, thereby playing a crucial role in the early detection and prevention of colorectal cancer.

What evidence supports the efficacy and safety of Motus GI's Pure-Vu System?

Motus GI has conducted clinical studies demonstrating the Pure-Vu System's ability to improve bowel cleanliness during colonoscopy, particularly in patients with inadequate preps. These studies have shown improved visualization scores and a reduction in aborted procedures. The system has received regulatory clearances, including FDA approval, indicating its safety and effectiveness for its intended use.

What is the typical pricing model for the Pure-Vu System, and what support does Motus GI offer to healthcare facilities?

The Pure-Vu System typically involves a capital equipment purchase for the main console, followed by recurring costs for disposable components used in each procedure. Motus GI provides comprehensive support, including installation, staff training, ongoing technical assistance, and clinical education to ensure optimal utilization and integration into existing endoscopy workflows.

How does Motus GI ensure compliance with medical device regulations and data security for its monitoring equipment and software?

Motus GI adheres to stringent medical device regulations, including FDA quality system regulations and ISO 13485 standards, for the design, manufacturing, and distribution of its products. While the Pure-Vu System primarily focuses on visualization and cleansing, any associated software or monitoring components would be developed with robust data security protocols and compliance with relevant privacy regulations like HIPAA to protect patient information.

What are Motus GI's strategic partnerships, and how do they impact product development or market reach?

Motus GI has established strategic partnerships with key players in the gastroenterology field, including leading medical device distributors and potentially academic institutions for research and development. These partnerships are crucial for expanding market access, facilitating product adoption, and gathering valuable clinical feedback to drive future product enhancements and innovations.

What is the long-term stability of Motus GI as a company, and what is their vision for future innovations in GI endoscopy?

Motus GI is a publicly traded company, and its financial stability can be assessed through its public filings. The company's vision for future innovations in GI endoscopy centers on further enhancing procedural efficiency, improving diagnostic accuracy, and expanding the utility of its technology to address a broader range of challenges in gastrointestinal care. This may include developing new applications for the Pure-Vu platform or introducing complementary technologies.

Related Companies

Suggest an Edit →